Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $48.8252W HIGH $85.76
Volume
339.43 K
Value Traded
36.02 M
Short % Float
9.8%
-0.05%Week
-2.29%1 Month
-7.94%3 Month
+18.29%6 Month
-11.02%5 Year
+6.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.21 B
EPS (TTM)
3.42
P/E Ratio
22.32
Ent. Value
3.98 B
Total Shares
55.12 M
Float Shares
54.87 M
Insiders
0.41%
Institutions
110.90%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LIVN Catalyst Timeline
Dated clinical, regulatory and corporate events for LivaNova PLC
Past FDA Catalysts and PDUFA Decisions
How LIVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
8
Drugs Scored
-
rNPV / MCap
Top 82%
Small Cap(rank 540 of 658)
Percentile Rank
LivaNova PLC faces pipeline headwinds (25/100), with 8 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every LIVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PolySync programming | obstructive sleep apnea | 2026-06-16 | In the OSPREY Study, LivaNova reported an 84.5% cumulative response rate for patients with obstructive sleep apnea treated with PolySync programming, indicating a significant improvement in symptoms and overall patient outcomes.Read More | LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep ApneaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bianchi FrancescoDirector | Sell | -3,500 4,434 held | $78.01 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LIVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.7 % (-46.2 %) | 20.96 M | 254.96 K | -55.07% ( -312.54 K) |
LIVN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LIVN ranks across every disease it competes in
Competitive Position is a premium feature
See how LIVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLIVN News
LIVNLivaNova to Announce Third-Quarter 2026 Results
LivaNova PLC will announce its third-quarter 2026 results during a conference call on November 4, 2026. The call is scheduled for 1 p.m. GMT and will be accessible via audiocast. The company plans to release the results prior to the call, emphasizing its commitment to transparency.
Read more →LIVNLivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
LivaNova PLC will present at the Morgan Stanley and Baird Healthcare Conferences in September. The presentations are scheduled for September 14 and 15 in New York City. CEO Vladimir Makatsaria and CFO Alex Shvartsburg will represent the company, highlighting its market-leading medical technologies.
Read more →LIVN▼ -8.4%on this news
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC reported a strong second quarter for 2026, with revenues reaching $390.6 million, marking a 10.8% increase compared to the previous year. The company also reported adjusted diluted earnings per share of $1.93. Additionally, LivaNova raised its full-year revenue guidance, reflecting positive growth expectations.
Read more →LIVNLivaNova to Announce Second-Quarter 2026 Results
LivaNova is set to announce its second-quarter results for 2026. The announcement is anticipated by investors and stakeholders. Further details regarding the financial performance and strategic outlook will be disclosed at that time.
Read more →LIVNLivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
LivaNova has reported an 84.5% cumulative response rate from its PolySync programming in the OSPREY study targeting obstructive sleep apnea. This promising outcome suggests potential advancements in the treatment of this condition. The results may pave the way for further developments in therapeutic options for patients.
Read more →LIVNJette Nygaard-Andersen Joins LivaNova Board as a New Director
Jette Nygaard-Andersen has been appointed as a new director on the board of LivaNova. This addition to the board is part of LivaNova's ongoing efforts to enhance its leadership team. The company aims to leverage her expertise in the biopharma sector to drive future growth.
Read more →LIVNLivaNova Appoints Anne Liddy as Chief Legal Officer
LivaNova has appointed Anne Liddy as its new Chief Legal Officer. This leadership change is part of the company's ongoing efforts to strengthen its executive team. Liddy brings extensive legal experience to the role, which may enhance the company's legal strategies moving forward.
Read more →LIVNLivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova has appointed Stefano Folli to lead its Cardiopulmonary Business Unit. This leadership change aims to enhance the company's focus on cardiopulmonary products and strategies. Further details regarding Folli's plans or the impact of this appointment have not been disclosed.
Read more →LIVNLivaNova to Present at Goldman Sachs Global Healthcare Conference in June 2026
LivaNova PLC announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 8, 2026. CEO Vladimir Makatsaria, CFO Alex Shvartsburg, and Chief Strategy Officer Phil Kowalczyk will engage in a fireside chat. The event will be available via webcast, with a replay accessible shortly after.
Read more →LIVNLivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LivaNova is scheduled to present at the Goldman Sachs Global Healthcare Conference in June. This event will provide an opportunity for the company to share insights and updates with investors and industry stakeholders. Further details about the presentation have not been disclosed.
Read more →LIVN▲ +15.1%on this news
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC reported a strong first quarter for 2026, with revenue rising to $362.3 million, a 14.3% increase from the previous year. The company also raised its full-year guidance for revenue growth and adjusted diluted earnings per share. Notably, LivaNova received FDA premarket approval for its aura6000™ System, marking a significant advancement in its product offerings for obstructive sleep apnea.
Read more →LIVNAnnals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
LivaNova's OSPREY clinical study published in the Annals of Internal Medicine shows that proximal hypoglossal nerve stimulation (pHGNS) significantly improves outcomes for patients with moderate to severe obstructive sleep apnea (OSA). The study, which involved a diverse patient population, demonstrated sustained improvements in apnea-hypopnea index, sleep quality, and patient-reported outcomes over 12 months. LivaNova plans to commercialize its aura6000 system for OSA treatment following FDA approval.
Read more →LIVNLivaNova to Announce First-Quarter 2026 Results
LivaNova PLC will announce its first-quarter 2026 results during a conference call on May 6, 2026. The call will take place at 1 p.m. London time and will be accessible via audiocast and telephone. A replay will be available on the company's website following the event.
Read more →LIVNLivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
LivaNova PLC reported strong financial results for Q4 and full-year 2025, highlighting double-digit revenue growth and improved operating margins. The company anticipates continued growth in 2026, projecting revenue increases of 6-7% and adjusted diluted earnings per share between $4.15 and $4.25. Despite a significant loss per share due to environmental liabilities, LivaNova remains optimistic about its future prospects in the OSA market.
Read more →LIVNLivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LivaNova PLC will hold a conference call on February 25, 2026, to discuss its fourth-quarter and full-year 2025 results. The results will be released prior to the call, which will be accessible via audiocast and telephone. A replay will be available on the company's website after the event.
Read more →LIVNLivaNova to Present at J.P. Morgan Healthcare Conference in January 2026
LivaNova PLC has announced its participation in the J.P. Morgan 44th Annual Healthcare Conference in January 2026. CEO Vladimir Makatsaria and CFO Alex Shvartsburg will engage in a fireside chat, which will be accessible via webcast. This event highlights LivaNova's commitment to sharing its vision and developments with a global audience.
Read more →LIVNLivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
LivaNova PLC has appointed Lucile Blaise as the Global Head of Commercialization for Obstructive Sleep Apnea, effective December 1. With over 25 years of experience in the medtech industry, Blaise aims to enhance patient access and drive growth in the OSA market. She previously held significant roles at ResMed, contributing to her expertise in sleep therapy.
Read more →LIVN▲ +12.3%on this news
LivaNova PLC Historical Recast of Segment Data Unaudited
LivaNova PLC has published an historical recast of segment data that reveals a mixed financial performance across various periods for 2022 and 2023. While total net revenues, particularly in the neuromodulation segment, show positive trends compared to the prior year, operating losses have been recorded, especially in certain quarters due to increased expenses. The data outlines both revenue growth and losses, illustrating the company's ongoing financial challenges in the market.
Read more →LIVNLivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility Announcement follows closing of underwritten offering of ordinary shares London
LivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility Announcement follows closing of underwritten offering of ordinary shares London, August 16, 2021 - LivaNova PLC (NASDAQ LIVN), a market-leading medical technology a
Read more →About LivaNova PLC
Headquarters5220 VALIANT COURT, GLOUCESTER
BIOPHARMAWATCH ELITE PLUS
Trade the next LIVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime